~~10/590,707~~ 10/590,707 Y=S or N

10/513699

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEAL1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR 7):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS	6	JUL 16	CAplus enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAplus patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	BEILSTEIN updated with new compounds
NEWS	12	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	13	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS	14	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS	15	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	16	AUG 27	USPATOLD now available on STN
NEWS	17	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	18	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	19	SEP 13	FORIS renamed to SOFIS
NEWS	20	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	21	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS	22	SEP 17	CAplus coverage extended to include traditional medicine patents

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

<12/04/2007> Erich Leese

10/513699

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:27:18 ON 21 SEP 2007

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY 0.21 TOTAL SESSION 0.21
FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 11:27:45 ON 21 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 SEP 2007 HIGHEST RN 947666-94-6
DICTIONARY FILE UPDATES: 20 SEP 2007 HIGHEST RN 947666-94-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10590707last.str

L1 STRUCTURE UPLOADED

=> s l1 full
FULL SEARCH INITIATED 11:28:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 15012 TO ITERATE

100.0% PROCESSED 15012 ITERATIONS 129 ANSWERS
SEARCH TIME: 00.00.01

L2 129 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY 172.10 TOTAL SESSION 172.31
FULL ESTIMATED COST 172.10 172.31

FILE 'CAPLUS' ENTERED AT 11:28:15 ON 21 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

<12/04/2007> Erich Leese

10/513699

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Sep 2007 VOL 147 ISS 14
FILE LAST UPDATED: 20 Sep 2007 (20070920/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l2 full
L3 15 L2

=> s l3 and py<2006
26210138 PY<2006
L4 11 L3 AND PY<2006

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:979639 CAPLUS
DOCUMENT NUMBER: 143:286443
TITLE: Preparation of pyrimidine derivatives as 5-HT3 receptor antagonists having agonistic activity on 5-HT1A
INVENTOR(S): Sato, Michitaka; Matsui, Teruaki; Asagarasu, Akira; Hayashi, Hiroyuki; Araki, Seiichi; Tamaoki, Satoru; Takahashi, Nobuyuki; Yamauchi, Yukinao; Yamamoto, Yoshiko; Yamamoto, Norio; Ogawa, Chisato
PATENT ASSIGNEE(S): Teikoku Hormone Mfg. Co., Ltd., Japan
SOURCE: PCT Int. Appl., 261 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082887	A1	20050909	WO 2005-JP3691	20050225 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,

<12/04/2007> Erich Leese

10/513699

EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2005217320	A1	20050909	AU 2005-217320	20050225 <--
CA 2557541	A1	20050909	CA 2005-2557541	20050225 <--
EP 1724267	A1	20061122	EP 2005-719969	20050225
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1922171	A	20070228	CN 2005-80005603	20050225
US 2007197551	A1	20070823	US 2006-590707	20060825
PRIORITY APPLN. INFO.:			JP 2004-52040	A 20040226
			JP 2004-322858	A 20041105
			WO 2005-JP3691	W 20050225

OTHER SOURCE(S): MARPAT 143:286443
GI



I

II

AB Title compds. I (ring A = carbocyclic group, etc.; X1 = H, amino, etc.; X2 = H, alkyl; Y = bond, etc.; n = 0-4; Ar = optionally substituted II with halo, etc.; Z = O, etc.; B = moiety required for completing mono-, ploy-heterocyclic ring containing N together with N-C-Z; dotted line indicates single, double bond) were prepared For example, treatment of potassium 3-amino-5,6-dimethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-2-thiolate with 2-[4-(3-chloropropyl)piperazin-1-yl]quinoline, e.g., prepared from piperazine in 2 steps, afforded 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one (III) in 50% yield. In 5-HT3 receptor affinity assay (in vitro), compound III exhibited the antagonistic activity of 94% at 10-7 M. Compds. I are claimed useful for the treatment of anxiety, depression, etc. Formulation is given.

IT 864385-05-7P 864385-12-6P 864385-49-9P
864385-51-3P 864385-58-0P 864385-61-5P
864385-71-7P 864385-72-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidine derivs. as 5-HT3 receptor antagonists having agonistic activity on 5-HT1A for treatment of anxiety, depression, etc.)

RN 864385-05-7 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidine-7(4H)-carboxylic acid, 3-amino-3,5,6,8-tetrahydro-4-oxo-2-[[3-[4-(2-quinolinyl)-1-

<12/04/2007> Erich Leese

piperazinyl]propyl]thio]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864385-12-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidine-7(4H)-carboxylic acid, 3-amino-2-[[3-[4-(2-benzothiazolyl)-1-piperazinyl]propyl]thio]-3,5,6,8-tetrahydro-4-oxo-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864385-49-9 CAPLUS
CN 7-Quinazolinecarboxylic acid, 3-amino-3,4-dihydro-4-oxo-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-51-3 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6,7,8-tetrahydro-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 864385-58-0 CAPLUS
CN Thieno[2,3-d]pyrimidine-6-carboxylic acid, 1,4-dihydro-5-methyl-4-oxo-2-[[3-[4-(2-pyridinyl)-1-piperazinyl]propyl]thio]-, ethyl ester (CA INDEX NAME)



RN 864385-61-5 CAPLUS
CN Thieno[2,3-d]pyrimidine-6-carboxylic acid, 1,4-dihydro-5-methyl-4-oxo-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]-, ethyl ester (CA INDEX NAME)



RN 864385-71-7 CAPLUS
CN Thieno[2,3-d]pyrimidine-6-carboxylic acid, 1,4-dihydro-5-methyl-4-oxo-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-72-8 CAPLUS

CN Thieno[2,3-d]pyrimidine-6-carboxylic acid, 1,4-dihydro-5-methyl-4-oxo-2-[[3-[4-(2-pyridinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



IT 864384-93-0P 864384-94-1P 864384-95-2P
864384-96-3P 864384-97-4P 864384-98-5P
864384-99-6P 864385-00-2P 864385-01-3P
864385-02-4P 864385-03-5P 864385-04-6P
864385-06-8P 864385-07-9P 864385-08-0P
864385-09-1P 864385-10-4P 864385-11-5P
864385-13-7P 864385-14-8P 864385-15-9P
864385-16-0P 864385-17-1P 864385-21-7P
864385-22-8P 864385-23-9P 864385-24-0P
864385-25-1P 864385-26-2P 864385-27-3P
864385-28-4P 864385-30-8P 864385-31-9P
864385-32-0P 864385-33-1P 864385-34-2P
864385-35-3P 864385-36-4P 864385-37-5P
864385-38-6P 864385-39-7P 864385-40-0P
864385-41-1P 864385-42-2P 864385-43-3P
864385-44-4P 864385-45-5P 864385-46-6P
864385-47-7P 864385-48-8P 864385-50-2P
864385-52-4P 864385-53-5P 864385-54-6P
864385-55-7P 864385-56-8P 864385-57-9P
864385-59-1P 864385-60-4P 864385-62-6P
864385-63-7P 864385-64-8P 864385-65-9P
864385-66-0P 864385-67-1P 864385-68-2P
864385-69-3P 864385-70-6P 864385-73-9P
864385-74-0P 864385-75-1P 864385-76-2P
864386-65-2P 864386-66-3P 864386-67-4P
864386-68-5P 864386-69-6P 864386-70-9P
864386-71-0P 864386-72-1P 864386-73-2P
864386-74-3P 864386-75-4P 864387-02-0P
864387-03-1P 864387-04-2P 864387-05-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine derivs. as 5-HT3 receptor antagonists having agonistic activity on 5-HT1A for treatment of anxiety, depression, etc.)

RN 864384-93-0 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6-dimethyl-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864384-94-1 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6-dimethyl-2-[[3-[4-(2-pyridinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864384-95-2 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6,7,8-tetrahydro-2-[[3-[4-(2-pyridinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864384-96-3 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6,7,8-tetrahydro-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864384-97-4 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6-dimethyl-2-[[3-(4-pyrrolo[1,2-a]quinoxalin-4-yl-1-piperazinyl)propyl]thio]- (CA INDEX NAME)



RN 864384-98-5 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-2-[[3-[4-(2-benzothiazolyl)-1-piperazinyl]propyl]thio]-5,6-dimethyl- (CA INDEX NAME)



RN 864384-99-6 CAPLUS
CN Thieno[3,2-d]pyrimidin-4(3H)-one, 3-amino-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-00-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-01-3 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6-dimethyl-2-[[4-[4-(2-quinolinyl)-1-piperazinyl]-2-butenyl]thio]- (9CI) (CA INDEX NAME)



RN 864385-02-4 CAPLUS
CN 7-Quinazolinecarboxylic acid, 3-amino-3,4-dihydro-4-oxo-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]-, ethyl ester (CA INDEX NAME)



RN 864385-03-5 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6-dimethyl-2-[[3-[4-(6-phenanthridinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-04-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-4,7-dione, 3-amino-3,5,6,8-tetrahydro-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-06-8 CAPLUS
CN Thieno[2,3-d]pyrimidine-6-carboxylic acid, 3-amino-3,4-dihydro-5-methyl-4-oxo-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]-, ethyl ester (CA INDEX NAME)



RN 864385-07-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-2-[[3-[4-(2-benzothiazolyl)-1-piperazinyl]propyl]thio]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 864385-08-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-7-nitro-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-09-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-2-[[3-[4-(2-benzothiazolyl)-1-piperazinyl]propyl]thio]-7-nitro- (CA INDEX NAME)



RN 864385-10-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-4,7-dione, 3-amino-2-[[3-[4-(2-benzothiazolyl)-1-piperazinyl]propyl]thio]-3,5,6,8-tetrahydro- (CA INDEX NAME)



RN 864385-11-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4(3H)-one, 3-amino-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-13-7 CAPLUS
CN Pyrido[3,2-d]pyrimidin-4(3H)-one, 3-amino-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-14-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4(3H)-one, 3-amino-2-[[3-[4-(2-benzothiazolyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-15-9 CAPLUS
CN Pyrido[3,2-d]pyrimidin-4(3H)-one, 3-amino-2-[[3-[4-(2-benzothiazolyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-16-0 CAPLUS
CN Cycloocta[4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6,7,8,9,10-hexahydro-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-17-1 CAPLUS
CN Cycloocta[4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-2-[[3-[4-(2-benzothiazolyl)-1-piperazinyl]propyl]thio]-5,6,7,8,9,10-hexahydro- (CA INDEX NAME)



RN 864385-21-7 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6,7,8-tetrahydro-5-methyl-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-22-8 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6,7,8-tetrahydro-6-methyl-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-23-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6,7,8-tetrahydro-7-methyl-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-24-0 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6-dimethyl-2-[[3-[4-(4-methyl-2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-25-1 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6,7,8-tetrahydro-2-[[3-[4-(4-methyl-2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-26-2 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-4,7-dione, 3-amino-3,5,6,8-tetrahydro-2-[[3-[4-(4-methyl-2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-27-3 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6-dimethyl-2-[[3-[4-(5,6,7,8-tetrahydro-2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-28-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6,7,8-tetrahydro-2-[[3-[4-(5,6,7,8-tetrahydro-2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-30-8 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-2-[[3-[4-(7-methoxy-1-isoquinolinyl)-1-piperazinyl]propyl]thio]-5,6-dimethyl- (CA INDEX NAME)



RN 864385-31-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6,7,8-tetrahydro-2-[[3-[4-(7-methoxy-1-isoquinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-32-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4(3H)-one, 3-amino-2-[[3-[4-(7-methoxy-1-isoquinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-33-1 CAPLUS
CN Pyrido[3,2-d]pyrimidin-4(3H)-one, 3-amino-2-[[3-[4-(7-methoxy-1-isoquinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-34-2 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-2-[[3-[4-(7-methoxy-3-methyl-1-isoquinolinyl)-1-piperazinyl]propyl]thio]-5,6-dimethyl- (CA INDEX NAME)



RN 864385-35-3 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6,7,8-tetrahydro-2-[[3-[4-(7-methoxy-3-methyl-1-isoquinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-36-4 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-2-[[3-[4-(5-methoxy-1-isoquinolinyl)-1-piperazinyl]propyl]thio]-5,6-dimethyl- (CA INDEX NAME)



RN 864385-37-5 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6,7,8-tetrahydro-2-[[3-[4-(5-methoxy-1-isoquinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-38-6 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-2-[[3-(4-furo[2,3-c]pyridin-7-yl-1-piperazinyl)propyl]thio]-5,6-dimethyl- (CA INDEX NAME)



RN 864385-39-7 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-2-[[3-(4-furo[3,2-c]pyridin-4-yl-1-piperazinyl)propyl]thio]-5,6-dimethyl- (CA INDEX NAME)



RN 864385-40-0 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-2-[[3-[4-(6-methoxy-1-isoquinolinyl)-1-piperazinyl]propyl]thio]-5,6-dimethyl- (CA INDEX NAME)



RN 864385-41-1 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6,7,8-tetrahydro-2-[[3-[4-(6-methoxy-1-isoquinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-42-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-43-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-2-[[3-[4-(4-methyl-2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-44-4 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-2-[[3-[4-(3-chloro-1-isoquinolinyl)-1-piperazinyl]propyl]thio]-5,6-dimethyl- (CA INDEX NAME)



RN 864385-45-5 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-2-[[3-[4-(3-chloro-1-isoquinolinyl)-1-piperazinyl]propyl]thio]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 864385-46-6 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6-dimethyl-2-[[3-[4-(3-methyl-2-quinoxalinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-47-7 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6,7,8-tetrahydro-2-[[3-[4-(3-methyl-2-quinoxalinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-48-8 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6-dimethyl-2-[[3-[4-(3-phenyl-2-quinoxalinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-50-2 CAPLUS
CN 4(3H)-Quinazolinone, 3,7-diamino-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-52-4 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-2-[[3-(4-(2-benzothiazolyl)-1-piperazinyl]propyl]thio]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 864385-53-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6,7,8-tetrahydro-2-[[3-[4-(4-methyl-2-quinolinyl)-1-piperazinyl]propyl]thio]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 864385-54-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-acetyl-3-amino-

5,6,7,8-tetrahydro-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-55-7 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-7-ethyl-5,6,7,8-tetrahydro-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-56-8 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(1H)-one, 5,6-dimethyl-2-[[3-[4-(2-pyridinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-57-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(1H)-one, 5,6,7,8-tetrahydro-2-[[3-[4-(2-pyridinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-59-1 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(1H)-one, 5,6-dimethyl-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-60-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(1H)-one, 5,6,7,8-tetrahydro-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-62-6 CAPLUS
CN 4(1H)-Quinazolinone, 2-[[3-[4-(2-benzothiazolyl)-1-piperazinyl]propyl]thio]- (9CI) (CA INDEX NAME)



RN 864385-63-7 CAPLUS
CN 4(1H)-Quinazolinone, 2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (9CI) (CA INDEX NAME)



RN 864385-64-8 CAPLUS

CN Thieno[2,3-d]pyrimidin-4(1H)-one, 5,6-dimethyl-2-[[3-(4-pyrrolo[1,2-a]quinoxalin-4-yl-1-piperazinyl)propyl]thio]- (CA INDEX NAME)



RN 864385-65-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(1H)-one, 5,6,7,8-tetrahydro-2-[[3-(4-pyrrolo[1,2-a]quinoxalin-4-yl-1-piperazinyl)propyl]thio]- (CA INDEX NAME)



RN 864385-66-0 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(1H)-one, 2-[[3-[4-(2-benzothiazolyl)-1-piperazinyl]propyl]thio]-5,6-dimethyl- (CA INDEX NAME)



RN 864385-67-1 CAPLUS
CN Thieno[3,2-d]pyrimidin-4(1H)-one, 2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (9CI) (CA INDEX NAME)



RN 864385-68-2 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(1H)-one, 5,6-dimethyl-2-[[4-[4-(2-quinolinyl)-1-piperazinyl]-2-butenyl]thio]- (9CI) (CA INDEX NAME)



RN 864385-69-3 CAPLUS
CN 4(1H)-Pyrimidinone, 6-propyl-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (9CI) (CA INDEX NAME)



RN 864385-70-6 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(1H)-one, 5,6-dimethyl-2-[[3-[4-(3-methyl-2-quinoxalinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-73-9 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(1H)-one, 6-amino-5-methyl-2-[[3-[4-(2-pyridinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-74-0 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(1H)-one, 6-amino-5-methyl-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864385-75-1 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(1H)-one, 5,6,7,8-tetrahydro-2-[[3-[4-(4-methyl-2-quinolinyl)-1-piperazinyl]propyl]thio]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 864385-76-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(1H)-one, 5,6,7,8-tetrahydro-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 864386-65-2 CAPLUS
CN 4(1H)-Quinazolinone, 5,6,7,8-tetrahydro-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 864386-66-3 CAPLUS
CN 4(1H)-Quinazolinone, 5,6,7,8-tetrahydro-2-[[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]amino]- (9CI) (CA INDEX NAME)



RN 864386-67-4 CAPLUS
CN 4(1H)-Quinazolinone, 5,6,7,8-tetrahydro-2-[[3-[4-(4-methyl-2-quinolinyl)-1-piperazinyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 864386-68-5 CAPLUS

CN 4(1H)-Quinazolinone, 5,6,7,8-tetrahydro-2-[[3-[4-(7-methoxy-1-isoquinolinyl)-1-piperazinyl]propyl]amino]- (9CI) (CA INDEX NAME)



RN 864386-69-6 CAPLUS
CN 4(1H)-Quinazolinone, 5,6,7,8-tetrahydro-2-[[3-(4-pyrrolo[1,2-a]quinoxalin-4-yl-1-piperazinyl)propyl]amino]- (9CI) (CA INDEX NAME)



RN 864386-70-9 CAPLUS
CN 4(1H)-Quinazolinone, 2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]amino]- (CA INDEX NAME)



RN 864386-71-0 CAPLUS
CN 4(1H)-Quinazolinone, 2-[[3-[4-(7-methoxy-1-isoquinolinyl)-1-piperazinyl]propyl]amino]- (CA INDEX NAME)



RN 864386-72-1 CAPLUS
CN 4(1H)-Quinazolinone, 2-[[3-(4-pyrrolo[1,2-a]quinoxalin-4-yl-1-piperazinyl)propyl]amino]- (CA INDEX NAME)



RN 864386-73-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]amino]- (CA INDEX NAME)



RN 864386-74-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]amino]- (CA INDEX NAME)



RN 864386-75-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6,7,8-tetrahydro-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]amino]- (CA INDEX NAME)



RN 864387-02-0 CAPLUS
CN 4(3H)-Quinazolinone, 5,6,7,8-tetrahydro-3-methyl-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864387-03-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-methyl-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864387-04-2 CAPLUS
CN 4(3H)-Quinazolinone, 5,6,7,8-tetrahydro-3-methyl-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]amino]- (CA INDEX NAME)



RN 864387-05-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-methyl-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]amino]- (CA INDEX NAME)



IT 864387-12-2 864387-13-3 864387-14-4
864387-15-5 864387-16-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of pyrimidine derivs. as 5-HT3 receptor antagonists having agonistic activity on 5-HT1A for treatment of anxiety, depression, etc.)

RN 864387-12-2 CAPLUS
CN Cycloocta[4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-2-[[3-[4-(2,4a-dihydro-2-quinolinyl)-1-piperazinyl]propyl]thio]-5,6,7,8,9,10-hexahydro- (CA INDEX NAME)



RN 864387-13-3 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6,7,8-tetrahydro-2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864387-14-4 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(1H)-one, 5,6,7,8-tetrahydro-2-[[3-[4-(4-methyl-2-quinolinyl)-1-piperazinyl]propyl]thio]- (CA INDEX NAME)



RN 864387-15-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]amino]- (CA INDEX NAME)



RN 864387-16-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(4-pyrrolo[1,2-a]quinoxalin-4-yl-1-piperazinyl)propyl]amino]- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:526514 CAPLUS
DOCUMENT NUMBER: 144:121488
TITLE: Antidepressant-like effect of D2/3 receptor-, but not D4 receptor-activation in the rat forced swim test
AUTHOR(S): Basso, Ana M.; Gallagher, Kelly B.; Bratcher, Natalie A.; Brioni, Jorge D.; Moreland, Robert B.; Hsieh, Gin C.; Drescher, Karla; Fox, Gerard B.; Decker, Michael W.; Rueter, Lynne E.
CORPORATE SOURCE: Neuroscience Research, Global Pharmaceutical Research & Development, Abbott Laboratories, Abbott Park, IL, USA
SOURCE: Neuropsychopharmacology (2005), 30(7), 1257-1268
CODEN: NEROEW; ISSN: 0893-133X
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Dopamine plays a role in the pathophysiol. of depression and therapeutic effects of antidepressants but the contribution of individual D2-like receptor subtypes (D2, D3, D4) to depression is not known. We present evidence that activation of D2/D3, but not D4 receptors, can affect the outcome in the rat forced swim test (FST). Nomifensine, a dopamine uptake inhibitor (7, 14, and 28 μmol/kg), quinpirole, a D2-like receptor and agonist (0.4, 1.0, and 2.0 μmol/kg), PD 12,8907, a preferential D3 receptor agonist (0.17, 0.35, and 0.7 μmol/kg), PD 168077 (0.1, 0.3, and 1.0 μmol/kg) and CP 226269 (0.3, 1.0, and 3.0 μmol/kg), both selective D4 receptor agonists, were administered s.c. 24, 5, and 0.5/1 h before testing. Nomifensine, quinpirole at all doses and PD 128907 at the highest dose decreased immobility time in FST. PD 168077 and CP 226269 had no effect on the model. To further clarify what type of dopamine receptors were involved in the anti-immobility effect of quinpirole, we tested different antagonists. Haloperidol, a D2-like receptor antagonist (0.27 μmol/kg), completely blocked the effect of quinpirole; A-437203

(LU-201640), a selective D3 receptor antagonist (17.46 μmol/kg), showed a nonsignificant trend to attenuate the effect of the low dose of quinpirole, and L-745,870, a selective D4 receptor antagonist (1.15 μmol/kg), had no effect. The pharmacol. selectivity of the compds. tested suggests that the antidepressant-like effects of quinpirole are most likely mediated mainly by D2 and to a lesser extent by D3 but not D4 receptors.
IT 220519-06-2, A 37203
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Lu 201640; D3 receptor antagonist L-745,870 showed non significant trend to block antidepressant effect of quinpirole in rat model for depression suggest antidepression effect of quinpirole less likely mediated by D3 receptor)
RN 220519-06-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-[4-[2-(1,1-dimethylethyl)-6-(trifluoromethyl)-4-pyrimidinyl]-1-piperazinyl]propyl]thio]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 93 THERE ARE 93 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:348194 CAPLUS
DOCUMENT NUMBER: 140:35303
TITLE: Multiconformational method for analyzing the biological activity of molecular structures
AUTHOR(S): Potemkin, V. A.; Arslambekov, R. M.; Bartashevich, E. V.; Grishina, M. A.; Belik, A. V.; Perspicace, S.; Guccione, S.
CORPORATE SOURCE: Chelyabinsk State University, Chelyabinsk, Russia
SOURCE: Journal of Structural Chemistry (Translation of Zhurnal Strukturnoi Khimii) (2002), 43(6), 1045-1049
CODEN: JSTCAM; ISSN: 0022-4766
PUBLISHER: Kluwer Academic/Consultants Bureau
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A multiconformational method for analyzing the biol. activity of compds. is proposed that combines conformer search algorithms and a 3D-QSAR receptor modeling procedure. The method allows one to find high-activity and low-activity conformers and determine the receptor shape. The biol. activity of a substance is determined as a superposition of the activities of its conformers with allowance for their proportions in the substance. Agreement between calculated and exptl. conformations and between calculated and exptl. biol. activities (pIC50%) is demonstrated by the example of agonists of the 5-HT1A receptor.
IT 185202-63-5 185202-78-2 185203-17-2 185203-19-4

RL: PAC (Pharmacological activity); BIOL (Biological study) (multiconformational method for analyzing the biol. activity of mol. structures)
RN 185202-63-5 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(1H)-one, 5,6-dimethyl-2-[[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]thio]- (9CI) (CA INDEX NAME)



RN 185202-78-2 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(1H)-one, 5,6,7,8-tetrahydro-2-[[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]thio]- (9CI) (CA INDEX NAME)



RN 185203-17-2 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3,5,6-trimethyl-2-[[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]thio]- (9CI) (CA INDEX NAME)



RN 185203-19-4 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6-dimethyl-2-[[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]thio]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:755251 CAPLUS
DOCUMENT NUMBER: 137:268478
TITLE: 2-{3-[4-(2-Tert-butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio}-4-pyrimidinol fumarate
INVENTOR(S): Hoger, Thomas; Starck, Dorothea; Treiber, Hans-Jorg; Schaefer, Bernd; Koser, Stefan; Thyes, Marco; Blank, Stefan
PATENT ASSIGNEE(S): Abbott Laboratories, Germany
SOURCE: U.S. Pat. Appl. Publ., 4 pp., Cont.-in-part of U.S. Appl. 2001 20,022.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20021431 79	A1	20021003	US 2002-39974	20020108 <--
US 6486162	B2	20021126		
DE 19735410	A1	19990218	DE 1997-19735410	19970814 <--
WO 9909015	A1	19990225	WO 1998-EP5178	19980814 <--
W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HR, HU, ID, IL, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, KG, MD, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 2001020022	A1	20010906	US 2000-485460	20000210 <--
PRIORITY APPLN. INFO.:			DE 1997-19735410 A	19970814
			WO 1998-EP5178 W	19980814
			US 2000-485460 A2	20000210

AB The fumaric acid salt of 2-{3-[4-(2-tert-butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio}-4-pyrimidinol (I) is useful for treating disorders which respond to dopamine D3 ligands. It has higher stability at low pH and is therefore particularly suitable for oral pharmaceutical compns. I was prepared in a series of steps starting by the reaction of 2,2-dimethylpropionamidine-HCl with Et trifluoroacetate in the presence of sodium methoxide in EtOH followed by subsequent treatments. I had unique advantages in stability over other acid addition salts.
IT 220519-06-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidinyl(piperazinyl)propylthiopyrimidinol fumarate for pharmaceuticals)
RN 220519-06-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-[4-[2-(1,1-dimethylethyl)-6-(trifluoromethyl)-4-pyrimidinyl]-1-piperazinyl]propyl]thio]- (9CI) (CA INDEX NAME)



IT 220519-07-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidinyl(piperazinyl)propylthiopyrimidinol fumarate for pharmaceuticals)
RN 220519-07-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-[4-[2-(1,1-dimethylethyl)-6-(trifluoromethyl)-4-pyrimidinyl]-1-piperazinyl]propyl]thio]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 220519-06-2
CMF C20 H27 F3 N6 O S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT 463331-19-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of pyrimidinyl(piperazinyl)propylthiopyrimidinol fumarate for pharmaceuticals)
RN 463331-19-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-[4-[2-(1,1-dimethylethyl)-6-(trifluoromethyl)-4-pyrimidinyl]-1-piperazinyl]propyl]thio]-, hydrate (9CI) (CA INDEX NAME)



●x H_2O

L4 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:730552 CAPLUS
DOCUMENT NUMBER: 135:267256
TITLE: Use of dopamine-D3 receptor ligands for the treatment of diseases of the central nervous system
INVENTOR(S): Starck, Dorothea; Treiber, Hans Joerg; Unger, Liliane; Teschendorf, Hans-juergen; Gross, Gerhard
PATENT ASSIGNEE(S): Basf Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001072306	A1	20011004	WO 2001-EP3411	20010326 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1272187	A1	20030108	EP 2001-923699	20010326 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003087917	A1	20030508	US 2002-239828	20020926 <--
PRIORITY APPLN. INFO.:			DE 2000-10015211 A	20000327
			WO 2001-EP3411 W	20010326

OTHER SOURCE(S): MARPAT 135:267256
AB The invention relates to the use of at least one compound of the general formula, L-D-B-G (L, G = aromatic, optionally heterocyclic groups, D = aliphatic
or heteroaliph. link, B = 6-, 7-, 8-membered, saturated or unsatd. ring, bound via the 1 position to D and via the 4 or 5 position to G, and having one or two nitrogen heteroatoms), for treating disorders of the central nervous system, and especially for treating psychiatric or neurol. disorders. The inventive compds. are especially useful in drug therapy.
IT 364079-69-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of dopamine-D3 receptor ligands for treatment of diseases of central nervous system)
RN 364079-69-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-[4-[2-(1,1-dimethylethyl)-6-(trifluoromethyl)-4-pyrimidinyl]-1-piperazinyl]propyl]thio]-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 220519-06-2
CMF C20 H27 F3 N6 O S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:67181 CAPLUS
DOCUMENT NUMBER: 134:311176
TITLE: Design, synthesis and binding properties of novel and selective 5-HT3 and 5-HT4 receptor ligands
AUTHOR(S): Modica, Maria; Santagati, Maria; Guccione, Salvatore; Russo, Filippo; Cagnotto, Alfredo; Goegan, Mara; Mennini, Tiziana
CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Universita di Catania, Catania, 95125, Italy
SOURCE: European Journal of Medicinal Chemistry (2000), 35(12), 1065-1079
CODEN: EJMCA5; ISSN: 0223-5234
PUBLISHER: Editions Scientifiques et Medicales Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:311176
GI



AB The synthesis and the binding tests on the 5-HT3 and 5-HT4 receptors of new thienopyrimidopiperazine and piperazinylacylaminodimethylthiophene derivs., in order to identify potent and selective ligands for each receptor, is reported. The compound with higher affinity and selectivity for the 5-HT3 over the 5-HT4 receptor was the 3-amino-2-(4-benzyl-1-piperazinyl)-5,6-dimethyl-thieno[2,3-d]pyrimidin-4(3H)-one (5-HT3 Ki = 3.92 nM, 5-HT4 not active), the compound with higher affinity and selectivity for the 5-HT4 over the 5-HT3 receptor was 2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butanoylamino]-4,5-dimethyl-3-thiophenecarboxylic acid Et ester (I) (5-HT4 Ki = 81.3 nM, 5-HT3 not active). Conformational analyses were carried out on the compds. of the piperazinylacylaminodimethylthiophene series taking I as the template.

IT 335275-09-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and binding properties of novel and selective 5-HT3 and 5-HT4 receptor ligands)

RN 335275-09-7 CAPLUS

CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6-dimethyl-2-[[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]thio]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:696300 CAPLUS

DOCUMENT NUMBER: 133:344185

TITLE: 3D-QSAR using "multiconformer" alignment: the use of HASL in the analysis of 5-HT1A thienopyrimidinone ligands

AUTHOR(S): Guccione, Salvatore; Doweyko, Arthur M.; Chen, Hongming; Barretta, Gloria Uccello; Balzano, Federica

CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Universita di Catania, Catania, I-95125, Italy

SOURCE: Journal of Computer-Aided Molecular Design (2000), 14(7), 647-657
CODEN: JCADEQ; ISSN: 0920-654X

PUBLISHER: Kluwer Academic Publishers

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The observed 5-HT1A and α1-adrenergic receptor (α1-AR) receptor binding properties of a series of 23 thienopyrimidinones were used to develop HASL 3D-QSAR models. A single, low energy conformer of the most active analog in the series, which was consistent with NMR structural studies, was chosen as a template mol. Alignments of all the mols. to the template were provided by an Amber/MM2 superposition force field. In this manner, each mol. was represented by five sep. low energy conformers which were subsequently used in the generation of HASL 3D-QSAR models. Models derived from multiple conformers were found to exhibit enhanced predictivity compared to models based on single, low energy conformers. In addition, the use of contour imaging of HASL multi-conformer model interactions was found to lead to a more consistent interpretation of those mol. features most significant for 5-HT1A receptor binding.

IT 185202-63-5 185202-78-2 185203-17-2
185203-19-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(3D-QSAR using "multiconformer" alignment: use of HASL in anal. of 5-HT1A thienopyrimidinone ligands)

RN 185202-63-5 CAPLUS

CN Thieno[2,3-d]pyrimidin-4(1H)-one, 5,6-dimethyl-2-[[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]thio]- (9CI) (CA INDEX NAME)



RN 185202-78-2 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(1H)-one, 5,6,7,8-tetrahydro-2-[[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]thio]- (9CI) (CA INDEX NAME)



RN 185203-17-2 CAPLUS

CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3,5,6-trimethyl-2-[[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]thio]- (9CI) (CA INDEX NAME)



RN 185203-19-4 CAPLUS

CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6-dimethyl-2-[[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]thio]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:379673 CAPLUS

DOCUMENT NUMBER: 133:171775

TITLE: High potent and selective arylpiperazine derivatives as ligands for the 5-HT1A receptor

AUTHOR(S): Modica, Maria; Santagati, Maria; Santagati, Andrea; Russo, Filippo; Cagnotto, Alfredo; Goegan, Mara; Mennini, Tiziana

CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Universita di Catania, Catania, 95125, Italy

SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(10), 1089-1092
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB This paper reports the synthesis of new arylpiperazinylalkylthiothienopyridine and thiadiazole derivs. and their affinities for the 5-HT1A vs. the α1A receptors. Most of the arylpiperazines show affinities values in the nanomolar range for the 5-HT1A receptor. One compound is highly potent (Ki 0.26nM, selectivity 28); two other derivs. are less potent, but highly selective (Ki 9.40 and 5.06nM, selectivity 207 and 73, resp.).

IT 288591-23-1P 288591-24-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and properties of arylpiperazinylalkylthiothienopyrimidine and -thiadiazole derivs. and their potency and selectivity as ligands for the 5-HT1A receptor)

RN 288591-23-1 CAPLUS

CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-6-ethyl-2-[[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]thio]- (9CI) (CA INDEX NAME)



RN 288591-24-2 CAPLUS

CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-2-[[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]thio]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:127124 CAPLUS

DOCUMENT NUMBER: 130:182482

TITLE: 2-[3-[4-(-tert-Butyl-6-trifluormethylpyrimidin-4-yl)piperazin-1-yl]propylthiol]pyrimidin-4-ol fumarate

INVENTOR(S): Blank, Stefan; Starck, Dorothea; Treiber, Hans-Joerg; Koeer, Stefan; Schaefer, Bernd; Thyes, Marco; Hoeger, Thomas

PATENT ASSIGNEE(S): BASF A.-G., Germany

SOURCE: Ger. Offen., 4 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19735410	A1	19990218	DE 1997-19735410	19970814 <--
TW 467912	B	20011211	TW 1998-87113230	19980812 <--
ZA 9807239	A	20000214	ZA 1998-7239	19980813 <--
IN 1998MA01839	A	20050304	IN 1998-MA1839	19980813 <--
CA 2301297	A1	19990225	CA 1998-2301297	19980814 <--
WO 9909015	A1	19990225	WO 1998-EP5178	19980814 <--
W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HR, HU, ID, IL, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, KG, MD, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9893426	A	19990308	AU 1998-93426	19980814 <--
AU 749575	B2	20020627		
TR 200000406	T2	20000522	TR 2000-200000406	19980814 <--
EP 1003728	A1	20000531	EP 1998-946343	19980814 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

BR 9811177	A	20000725	BR 1998-11177	19980814	<--
NZ 502675	A	20010629	NZ 1998-502675	19980814	<--
JP 2001515070	T	20010918	JP 2000-509698	19980814	<--
HU 200003710	A2	20011028	HU 2000-3710	19980814	<--
IL 134246	A	20021110	IL 1998-134246	19980814	<--
MX 200001161	A	20001116	MX 2000-1161	20000202	<--
BG 104122	A	20001130	BG 2000-104122	20000203	<--
NO 2000000665	A	20000210	NO 2000-665	20000210	<--
NO 314935	B1	20030616			
US 2001020022	A1	20010906	US 2000-485460	20000210	<--
US 2002143179	A1	20021003	US 2002-39974	20020108	<--
US 6486162	B2	20021126			

PRIORITY APPLN. INFO.: DE 1997-19735410 A 19970814
WO 1998-EP5178 W 19980814
US 2000-485460 A2 20000210

AB The title compound was prepared from the pyrimidine, piperazine,a nd thiouracil fragments. The fumarate had a half-life in 1N HCl that was >5 times longer than that of the free base, indicating much greater stability to stomach acid for the fumarate.

IT 220519-06-2P
RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation and acid stability of 2-[3-[4-(-tert-butyl-6-trifluormethylpyrimidin-4-yl)piperazin-1-yl]propylthio]pyrimidin-4-ol fumarate)

RN 220519-06-2 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[[3-[4-[2-(1,1-dimethylethyl)-6-(trifluoromethyl)-4-pyrimidinyl]-1-piperazinyl]propyl]thio]- (9CI) (CA INDEX NAME)



IT 220519-07-3P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and acid stability of 2-[3-[4-(-tert-butyl-6-trifluormethylpyrimidin-4-yl)piperazin-1-yl]propylthio]pyrimidin-4-ol fumarate)

RN 220519-07-3 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[[3-[4-[2-(1,1-dimethylethyl)-6-(trifluoromethyl)-4-pyrimidinyl]-1-piperazinyl]propyl]thio]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 220519-06-2
CMF C20 H27 F3 N6 O S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:80137 CAPLUS
DOCUMENT NUMBER: 126:69742
TITLE: [[(Arylpiperazinyl)alkyl]thio]thieno[2,3-d]pyrimidinone Derivatives as High-Affinity, Selective 5-HT1A Receptor Ligands
AUTHOR(S): Modica, Maria; Santagati, Maria; Russo, Filippo; Parotti, Luca; De Gioia, Luca; Selvaggini, Carlo; Salmona, Mario; Mennini, Tiziana
CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Universita di Catania, Catania, 95125, Italy
SOURCE: Journal of Medicinal Chemistry (1997), 40(4), 574-585
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A series of 2-[[(4-aryl-1-piperazinyl)alkyl]thio]thieno[2,3-d]pyrimidin-4(1H)-one and 3-substituted 2-[[(4-aryl-1-piperazinyl)alkyl]thio]thieno[2,3-d]pyrimidin-4(3H)-one derivs. was prepared and evaluated for in vitro 5-HT1A receptor affinity by radioligand binding assays; the selectivity for 5-HT1A receptors rather than α1-adrenoceptors was also examined (ratio of the IC50 α1 to IC50 5-HT1A). The binding tests gave indications about the best features of the [(arylpiperazinyl)alkyl]thio moiety and of the substituents on the thiophene and pyrimidinone rings for efficacious and selective 5-HT1A ligands. The most effective derivative for displacing [3H]-8-OH-DPAT from rat hippocampal membranes was 3-amino-2-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]thio]-5,6-dimethylthieno[2,3-d]pyrimidin-4(3H)-one (IC50 = 0.3 nM) with selectivity of 24 for the 5-HT1A over the α1-adrenoceptor. Another compound, where the 2-methoxyphenyl on the N4 piperazine ring was replaced with a pyrimidine group, showed the best selectivity, with a ratio of 74, while its affinity IC50 for 5-HT1A was 6.8 nM. The results showed the importance of an amino group in position 3 of the thienopyrimidine system for the interaction with 5-HT1A receptor binding sites, although this fragment can affect the affinity and selectivity only if linked to the

(arylpiperazinyl)alkyl moiety. Twenty of the 30 mols. used for determining the binding affinity to 5-HT1A and α1-adrenergic receptors were selected for QSAR anal. using a series of mol. descriptors and calculated with the TSAR software.

IT 185202-63-5P 185202-78-2P 185203-17-2P
185203-19-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazinyl thienopyrimidinones as 5-HT1A receptor ligands)

RN 185202-63-5 CAPLUS

CN Thieno[2,3-d]pyrimidin-4(1H)-one, 5,6-dimethyl-2-[[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]thio]- (9CI) (CA INDEX NAME)



RN 185202-78-2 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(1H)-one, 5,6,7,8-tetrahydro-2-[[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]thio]- (9CI) (CA INDEX NAME)



RN 185203-17-2 CAPLUS

CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3,5,6-trimethyl-2-[[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]thio]- (9CI) (CA INDEX NAME)



RN 185203-19-4 CAPLUS

CN Thieno[2,3-d]pyrimidin-4(3H)-one, 3-amino-5,6-dimethyl-2-[[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]thio]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:211777 CAPLUS
DOCUMENT NUMBER: 124:261075
TITLE: Preparation of 2-(piperazinoalkylthio)pyrimidines and analogs as dopamine D3 receptor ligands
PATENT ASSIGNEE(S): BASF A.-G., Germany
SOURCE: Ger. Offen., 17 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
DE 4425143	A1	19960118	DE 1994-4425143	19940715	<--
CA 2195241	A1	19960201	CA 1995-2195241	19950714	<--
WO 9602519	A1	19960201	WO 1995-EP2784	19950714	<--
W: AU, BG, BR, CA, CN, CZ, FI, HU, JP, KR, MX, NO, NZ, RU, SI, UA, US					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
AU 9531116	A	19960216	AU 1995-31116	19950714	<--
AU 703857	B2	19990401			
ZA 9505868	A	19970114	ZA 1995-5868	19950714	<--
EP 772603	A1	19970514	EP 1995-926898	19950714	<--
EP 772603	B1	20020612			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
CN 1152917	A	19970625	CN 1995-194141	19950714	<--
CN 1124269	B	20031015			
JP 10502659	T	19980310	JP 1996-504703	19950714	<--
JP 3819024	B2	20060906			
HU 77535	A2	19980528	HU 1997-113	19950714	<--
IL 114599	A	19990817	IL 1995-114599	19950714	<--
RU 2172736	C2	20010827	RU 1997-102159	19950714	<--
AT 219063	T	20020615	AT 1995-926898	19950714	<--
PT 772603	T	20021129	PT 1995-926898	19950714	<--
ES 2178676	T3	20030101	ES 1995-926898	19950714	<--
CZ 295346	B6	20050713	CZ 1997-123	19950714	<--
TW 455587	B	20010921	TW 1995-84108221	19950808	<--
BG 63257	B1	20010731	BG 1997-101110	19970106	<--
FI 9700150	A	19970114	FI 1997-150	19970114	<--
NO 9700162	A	19970314	NO 1997-162	19970114	<--
NO 312030	B1	20020304			
US 6342604	B1	20020129	US 1997-765292,	19970114	<--
US 6444674	B1	20020903	US 2001-940937	20010829	<--

PRIORITY APPLN. INFO.: DE 1994-4425143 A 19940715
WO 1995-EP2784 W 19950714
US 1997-765292 A3 19970114

OTHER SOURCE(S): MARPAT 124:261075

GI



I

II

AB Title compds. [I; R = (un)substituted Ph, -pyridyl, -pyrimidyl, -triazinyl; R1-R3 = H, halo, OH, alkoxy, (di)(alkyl)amino, etc.; Z1 = (O-, NH-, CO2-, etc.-interrupted or -terminated) alk(en)ylene, etc.; Z2 = piperazine-1,4-diyl, piperidinylene, etc.] were prepared as dopamine D3 receptor ligands (no data). Thus, 2-mercaptopyrimidine was thioetherified by 1-bromo-5-chloropentane and the product aminated by 1-(3-trifluoromethylphenyl)piperazine to give title compound II.

IT 175156-93-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-(piperazinoalkylthio)pyrimidines and analogs as dopamine D3 receptor ligands)

RN 175156-93-1 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[[4-[4-[6-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-butenyl]thio]- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 11:27:18 ON 21 SEP 2007)

FILE 'REGISTRY' ENTERED AT 11:27:45 ON 21 SEP 2007
L1 STRUCTURE UPLOADED
L2 129 S L1 FULL

FILE 'CAPLUS' ENTERED AT 11:28:15 ON 21 SEP 2007
L3 15 S L2 FULL
L4 11 S L3 AND PY<2006

<12/04/2007> Erich Leese

10/590,707

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	223	(544/55,544/88,544/250,544/255, 544/249,544/253,514/267,514/260. 1,514/264.1,514/228.8,514/222.2). CCLS.	US-PGPUB; USPAT	OR	OFF	2007/09/21 09:42
L2	44	l1 and pyrimidine	US-PGPUB; USPAT	OR	ON	2007/09/21 09:44
L3	15	l2 and piperazine	US-PGPUB; USPAT	OR	ON	2007/09/21 09:44
L4	12	l3 and carbonyl	US-PGPUB; USPAT	OR	ON	2007/09/21 09:44
L5	12	l4 and alkyl	US-PGPUB; USPAT	OR	ON	2007/09/21 09:55
L6	280	l5 and (piperidine or pyridine) or 1, 3-oxazine or 1,3-thiazine	US-PGPUB; USPAT	OR	ON	2007/09/21 09:52